Antifungal drugs can affect the cellular morphology of Cryptococcus neoformans in culture, which alters its interactions with phagocytes. We examined the effects of amphotericin B on C. neoformans during murine infection. The antifungal reduced capsule size and serum polysaccharide, which suggests an additional mechanism for amphotericin B's efficacy in cryptococcosis.
distilled H 2 O to lyse mammalian cells. Aliquots of the cell preparations were plated onto Sabouraud agar (one colony ϭ 1 CFU). India ink preparations were viewed with an Olympus AX70 (Melville, NY) microscope, and images were obtained (QImaging Retiga 1300 digital camera [Burnaby, British Columbia, Canada]) with QCapture Suite V2.46 software (QImaging). Capsule thickness was determined by subtracting the diameter of the cell body from that of the whole cell (capsule plus cell body). Three mice were sacrificed per sample, and at least 200 cells were counted per mouse. Significance was determined by t test or Kruskal-Wallis test.
Serum samples from mice were collected at day 7 after infection. The sera were treated with proteinase K (1 mg/ml; Roche, IN) and then used in a capture enzyme-linked immunosorbent assay (ELISA) to determine the quantity of circulating glucuronoxylomannan (GXM), the major component of C. neoformans polysaccharide (4). GXM levels were calculated relative to H99 GXM standards (2) . The Kruskal-Wallis test was used to analyze differences in GXM levels.
During pulmonary infection, the capsule of C. neoformans dramatically increases in size (8) in as little as 5 min after infection and is most pronounced after 24 h of infection. This increase in capsule size is thought to be important in pathogenesis (13) . The CFU at day 1 after infection were similar in the three groups of mice, and propidium iodide staining showed a viability of Ͼ97% (data not shown). After 1 and 7 days of infection, C. neoformans isolated from control mice showed a significant increase in capsule size (Fig. 1 ). In contrast, C. neoformans isolated at day 7 after infection from mice treated with AMB (1 mg/kg) had bigger cell body sizes and smaller capsules (Fig. 1 ). This result suggests that AMB arrests the cells at a stage where the cells are bigger but the capsule is proportionally smaller. Although the cell size at day 1 was more homogeneous than for the control, the 0.25-mg/kg dose did not result in a significant morphological effect (Fig. 1) . Homogeneity may benefit the host immune response, since heterogeneity of C. neoformans cells has been linked to dissemination (3). We examined the effect of the antifungals relative to the fungal burden in the lung at day 7 after infection. At the concentrations of drugs examined, treatment with AMB was associated with a significant reduction in the number of yeast cells present in the lung (Fig. 2A) . Measurement of GXM concentration in serum revealed that the higher dose of AMB significantly reduced the capsular polysaccharide levels (Fig. 2B ). There was a trend toward a reduction in serum GXM levels with the lower dose. Hence, AMB can alter C. neoformans morphology and reduce the CFU in the lung and the GXM levels in serum.
Our results suggest that, in addition to the direct effects of AMB on the fungal cell membrane, it can significantly affect the development and release of polysaccharide capsule. To our knowledge this finding is the first evidence that AMB alters C. neoformans cellular characteristics in vivo. This issue is relevant to the mechanism of AMB antifungal action, since this drug has a large volume of distribution and its concentration in tissue may be below the fungicidal threshold (5-7, 12, 18) . In this regard AMB has been shown to be relatively ineffective against C. neoformans in nude mice, suggesting that its direct antifungal effects alone are insufficient to modify infection in severely immunocompromised hosts (9) . Our results showing a change in cryptococcal cellular morphology imply that indirect mechanisms are important factors in the activity of AMB.
Although the benefits of a large capsule have not been well characterized in vivo, it is reasonable to consider that this increase confers a selective advantage during infection, such as a mechanism to avoid phagocytosis (11) . Furthermore, the polysaccharide capsule has potent anti-inflammatory activities (10, 20) . However, the data should be carefully interpreted, since capsule growth occurs in the first hours of infection (8) . We interpret our results as a consequence of a lower yeast growth rate due to the presence of the antifungal drug, which would result in cells with larger cell bodies. In summary, we investigated the effects of AMB on the pathogenic fungus C. neoformans during murine infection and show changes in some of the parameters related to infection, such as CFU, GXM 
